RT @NaraYoon12: To study such a method to utilize existing drugs, we previously made a simplified (2 state, ODE based) mathematical model a…
RT @CancerConnector: @NaraYoon12 's paper builds off her first work in @SMB_MathBiology BMB showing how to optimally schedule TWO collatera…
RT @CancerConnector: @NaraYoon12 's paper builds off her first work in @SMB_MathBiology BMB showing how to optimally schedule TWO collatera…
@NaraYoon12 's paper builds off her first work in @SMB_MathBiology BMB showing how to optimally schedule TWO collaterally sensitive drugs: https://t.co/bAZcyoSlEf 2/n
RT @NaraYoon12: To study such a method to utilize existing drugs, we previously made a simplified (2 state, ODE based) mathematical model a…
To study such a method to utilize existing drugs, we previously made a simplified (2 state, ODE based) mathematical model and studied the effects of pair of hypothetical drugs that induce collateral sensitivity to one another. (3/n) https://t.co/hJXiEBega6
RT @CancerConnector: After just three years, she has had four papers (one more in the works), including this influential work where she is…
After just three years, she has had four papers (one more in the works), including this influential work where she is able to prove an optimal chemo dosing strategy for an evolving population: https://t.co/bAZcyoSlEf #mathonco
Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs published as: https://t.co/RdrgAkzdRL @springerpub #biorxiv
RT @caseccc: & collaboration with our friends at @MoffittNews! https://t.co/NvzGLOWkWu
& collaboration with our friends at @MoffittNews!
@CCLRI @cwru @caseccc @bikeVeloSano @mikemorrison @nkrishnan94 @CWRUSOM @baym @erinmc595 @evokerr @vscooper More abstractly, superstar post-doc @NaraYoon12 (soon to be faculty at @AdelphiU ) is showing off her work understanding drug timing and ordering in
@ara_anderson @cgatenbee @biorxivpreprint @mathonco @research_junkie we’re thinking about trying to give it a go with @NaraYoon12 ’s new paper extending her 2 species optimal therapy results to N… #mathonco https://t.co/bAZcyoSlEf
That #mathonco paper of @NaraYoon12 ‘a can be found here https://t.co/0mE1pwf2q9
RT @CancerConnector: Specifically @HochTwit - see recent paper here: https://t.co/0mE1pwwDhH #ISEMPH2018
Specifically @HochTwit - see recent paper here: https://t.co/0mE1pwwDhH #ISEMPH2018
@aakhmetz @dbasanta Interesting looking #mathonco preprint. Eager to read closer to see how it differs from @NaraYoon12 ‘s recent @SMB_MathBiology paper: https://t.co/0mE1pwf2q9
RT @SMBDigest: Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs by Yoon, Vander Velde, Marusyk, Scott in Flagship…
Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs by Yoon, Vander Velde, Marusyk, Scott in Flagship Journal of @SMB_MathBiology #BMB #BullMathBio #mathbio https://t.co/IspwNnN8h8
RT @CancerConnector: @ara_anderson @NaraYoon12 is a brilliant #womaninstem in our group - an expert in dynamical systems & disease modeling…
@ara_anderson @NaraYoon12 is a brilliant #womaninstem in our group - an expert in dynamical systems & disease modeling, she did her PhD in math @cwru modeling malaria before she made the shift to #cancer. She published a great paper on adaptive therapy
RT @CancerConnector: @NaraYoon12 set up a piecewose continuous dynamical system to study the optimal switching time between two collaterall…
RT @CancerConnector: @NaraYoon12 set up a piecewose continuous dynamical system to study the optimal switching time between two collaterall…
@NaraYoon12 set up a piecewose continuous dynamical system to study the optimal switching time between two collaterally sensitive drugs. Very nice new paper in @SMB_MathBiology flagship journal here: https://t.co/0mE1pwf2q9 #mathonco https://t.co/m2VdHtC9H
RT @CancerConnector: @cmaley Paper here: https://t.co/0mE1pwf2q9 #EvolTherapy18
@cmaley Paper here: https://t.co/0mE1pwf2q9 #EvolTherapy18
RT @EvolTherapy: .@CancerConnector now discuss very recent work from his lab by @NaraYoon12 https://t.co/TgSekFQRnN #EvolTherapy18 https:…
.@CancerConnector now discuss very recent work from his lab by @NaraYoon12 https://t.co/TgSekFQRnN #EvolTherapy18 https://t.co/pgQtcsMURs
RT @CancerConnector: Bob’s on the money, as usual. @NaraYoon12 just mathematically introduced the concept Bob just came across intuitively!…
RT @NaraYoon12: Yes, we figured out 't_min', especially for two-drug therapy. And, now we are expanding our research to n-drug cases. :) ht…
RT @CancerConnector: Bob’s on the money, as usual. @NaraYoon12 just mathematically introduced the concept Bob just came across intuitively!…
RT @CancerConnector: Bob’s on the money, as usual. @NaraYoon12 just mathematically introduced the concept Bob just came across intuitively!…
RT @CancerConnector: Bob’s on the money, as usual. @NaraYoon12 just mathematically introduced the concept Bob just came across intuitively!…
Yes, we figured out 't_min', especially for two-drug therapy. And, now we are expanding our research to n-drug cases. :) https://t.co/FappxBf6Mx
RT @CancerConnector: Bob’s on the money, as usual. @NaraYoon12 just mathematically introduced the concept Bob just came across intuitively!…
Bob’s on the money, as usual. @NaraYoon12 just mathematically introduced the concept Bob just came across intuitively! We call it ’t_min’ - it's the time to introduce the second drug - and it’s before the failure of the 1st https://t.co/0mE1pwf2q9 @SMB_Ma
RT @CancerConnector: First paper out of our new lab in @CCLRI - more to come soon! #mathonco in Cleveland! https://t.co/6qvYi3j055
RT @CancerConnector: @AndriyMarusyk highlights theoretical work together with @NaraYoon12 in two different projects. Great example@of stro…
RT @CancerConnector: @AndriyMarusyk highlights theoretical work together with @NaraYoon12 in two different projects. Great example@of stro…
@AndriyMarusyk highlights theoretical work together with @NaraYoon12 in two different projects. Great example@of strong inter-disciplinary work! #evodiv18 paper here: https://t.co/0mE1pwf2q9 https://t.co/JuYAEBrMBH
RT @CancerConnector: First paper out of our new lab in @CCLRI - more to come soon! #mathonco in Cleveland! https://t.co/6qvYi3j055
RT @CancerConnector: Ver proud of @NaraYoon12 - first post-doc paper now out in @SMB_MathBiology Bulletin! Optimal Therapy Scheduling Based…
RT @CancerConnector: First paper out of our new lab in @CCLRI - more to come soon! #mathonco in Cleveland! https://t.co/6qvYi3j055
RT @CancerConnector: First paper out of our new lab in @CCLRI - more to come soon! #mathonco in Cleveland! https://t.co/6qvYi3j055
RT @CancerConnector: Ver proud of @NaraYoon12 - first post-doc paper now out in @SMB_MathBiology Bulletin! Optimal Therapy Scheduling Based…
RT @CancerConnector: First paper out of our new lab in @CCLRI - more to come soon! #mathonco in Cleveland! https://t.co/6qvYi3j055
RT @CancerConnector: Ver proud of @NaraYoon12 - first post-doc paper now out in @SMB_MathBiology Bulletin! Optimal Therapy Scheduling Based…
RT @CancerConnector: Ver proud of @NaraYoon12 - first post-doc paper now out in @SMB_MathBiology Bulletin! Optimal Therapy Scheduling Based…
RT @CancerConnector: First paper out of our new lab in @CCLRI - more to come soon! #mathonco in Cleveland! https://t.co/6qvYi3j055
RT @CancerConnector: Ver proud of @NaraYoon12 - first post-doc paper now out in @SMB_MathBiology Bulletin! Optimal Therapy Scheduling Based…
RT @CancerConnector: First paper out of our new lab in @CCLRI - more to come soon! #mathonco in Cleveland! https://t.co/6qvYi3j055
RT @CancerConnector: Ver proud of @NaraYoon12 - first post-doc paper now out in @SMB_MathBiology Bulletin! Optimal Therapy Scheduling Based…
RT @CancerConnector: First paper out of our new lab in @CCLRI - more to come soon! #mathonco in Cleveland! https://t.co/6qvYi3j055
RT @CancerConnector: First paper out of our new lab in @CCLRI - more to come soon! #mathonco in Cleveland! https://t.co/6qvYi3j055
First paper out of our new lab in @CCLRI - more to come soon! #mathonco in Cleveland! https://t.co/6qvYi3j055
Ver proud of @NaraYoon12 - first post-doc paper now out in @SMB_MathBiology Bulletin! Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs #mathonco #greenlion https://t.co/bAZcyoSlEf